Summary & Overview
CPT 81257: HBA1/HBA2 Sequencing for Alpha Thalassemia
CPT code 81257 covers molecular testing that detects specific sequence changes and potential deletions in the HBA1 and HBA2 genes to evaluate alpha thalassemia and related hemoglobinopathies. This genetic diagnostic test is clinically important because it informs diagnosis, carrier screening, and clinical management for patients with microcytic anemia or suspected hemoglobin structural variants. Nationally, molecular hemoglobinopathy testing is relevant to prenatal screening programs, hematology practice, and hereditary disease panels.
Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical purpose of the test, where the service is typically performed, and which major payers are commonly involved. The publication also summarizes available benchmarks and common billing practices, highlights policy considerations for coverage of molecular diagnostic assays, and outlines the clinical context in which CPT code 81257 is most often used.
The content is intended for billing specialists, laboratory directors, and health policy analysts seeking a concise reference on the code’s clinical role, payer landscape, and the types of insights normally covered in reimbursement and utilization summaries. Data not available in the input will be noted where applicable.
Billing Code Overview
CPT code 81257 describes a molecular diagnostic laboratory test that detects specific sequence changes and possible nucleotide deletions in the alpha globin 1 (HBA1) and alpha globin 2 (HBA2) genes. The assay is used to identify genetic variants associated with alpha thalassemia and other structural hemoglobinopathies.
Service Type: Genetic sequencing / molecular diagnostic testing
Typical Site of Service: Clinical molecular diagnostics laboratory
Clinical & Coding Specifications
Clinical Context
A patient is referred to a molecular diagnostics laboratory after abnormal hemoglobin testing or a family history of thalassemia. Typical patients include an adult with microcytic anemia unresponsive to iron therapy, a pregnant patient undergoing carrier screening, or a newborn/child with unexplained anemia or abnormal newborn screening results. The clinician (hematologist, obstetrician, pediatrician, or primary care physician) orders targeted sequencing or deletion/duplication analysis of the alpha globin genes to detect point mutations, small insertions/deletions, or common gene deletions in HBA1 and HBA2.
Blood is drawn in an appropriate EDTA tube and sent to the molecular lab. The laboratory analyst performs DNA extraction, PCR-based or sequencing-based assays (such as targeted NGS or gap-PCR), interprets detected variants relative to reference sequences, and generates a report describing pathogenic, likely pathogenic, benign, or variants of uncertain significance relevant to alpha thalassemia and structural hemoglobinopathies. Results are routed back to the ordering provider for genetic counseling, carrier screening decisions, prenatal counseling, or management of patients with symptomatic anemia. Typical site of service is an outpatient clinic for specimen collection and a clinical molecular laboratory (reference or hospital-based) for testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|